UK Markets closed

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
272.23+2.29 (+0.85%)
As of 3:46PM EDT. Market open.

Biogen Inc.

225 Binney Street
Cambridge, MA 02142
United States
617 679 2000
http://www.biogen.com

Sector(s)Healthcare
IndustryDrug Manufacturers—General
Full-time employees9,100

Key executives

NameTitlePayExercisedYear born
Mr. Michel VounatsosCEO & Director4.51MN/A1962
Mr. Michael R. McDonnellExec. VP & CFO1.56MN/A1964
Ms. Susan H. AlexanderExec. VP, Chief Legal Officer & Sec.1.58MN/A1957
Dr. Alfred W. Sandrock Jr., M.D., Ph.D.Exec. VP of R&D1.76MN/A1958
Mr. Chirfi GuindoExec. VP of Global Product Strategy & Commercialization1.17MN/A1966
Ms. Robin C. KramerSr. VP & Chief Accounting OfficerN/AN/A1966
Mr. Michael HenckeDirector of Investor RelationsN/AN/AN/A
Ms. Natacha GassenbachChief Communication Officer & Head of Corp. AffairsN/AN/AN/A
Dr. Ginger GregoryExec. VP & Chief HR OfficerN/AN/A1968
Dr. Alphonse GaldesExec. VP of Pharmaceutical Operations & TechnologyN/AN/A1953
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Biogen Inc.’s ISS governance QualityScore as of 1 July 2021 is 7. The pillar scores are Audit: 6; Board: 4; Shareholder rights: 3; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.